Isigaba sesi-2 sovavanyo lwezonyango lwe-Retatrutide, i-Triple Hormone-Receptor Agonist, yoNyango lokutyeba kakhulu.

Imvelaphi kunye noYilo lweSifundo

I-Retatrutide (LY3437943) lichiza lenoveli enye-peptide esebenzayoezintathu receptors ngaxeshanye: GIP, GLP-1, kunye neglucagon. Ukuvavanya ukusebenza kwayo kunye nokukhuseleka kwabantu abanokukhuluphala kodwa bengenaso isifo sikashukela, isigaba se-2, i-randomized, i-double-blind, isilingo esilawulwa yi-placebo senziwe (NCT04881760). Iyonke yeNgama-338 abathathi-nxaxhebakunye ne-BMI ≥30, okanye i-≥27 ubuncinane kunye ne-comorbidity enye ehambelana nobunzima, i-randomized ukufumana i-placebo okanye i-retatrutide (i-1 mg, i-4 mg kunye neeshedyuli ezimbini ze-titration, i-8 mg kunye neeshedyuli ezimbini ze-titration, okanye i-12 mg) elawulwa kanye ngeveki nge-injection subcutaneous kwiiveki ze-48. Iinqanaba lokuqalayayiyipesenti yokuguqulwa kobunzima bomzimba kwiiveki ze-24, kunye nesiphelo sesibini esibandakanya ukuguqulwa kwesisindo kwiiveki ze-48 kunye nemigangatho ye-categorical weight-lossholds (≥5%, ≥10%, ≥15%).

Iziphumo eziphambili

• Iiveki ezingama-24: Ubuncinci-izikwere zithetha utshintsho lwepesenti kwisisindo somzimba ngokumalunga nesiseko

  • Indawo: −1.6%

  • 1 mg: -7.2%

  • 4 mg (idibene): -12.9%

  • 8 mg (idibene): -17.3%

  • 12 mg: -17.5%

• Iiveki ezingama-48: Ipesenti yokutshintsha ubunzima bomzimba yayi

  • Indawo: −2.1%

  • 1 mg: -8.7%

  • 4 mg (idibene): -17.1%

  • 8 mg (idibene): -22.8%

  • 12 mg: -24.2%

Kwiiveki ezingama-48, umyinge wabathathi-nxaxheba abaphumeza imida yokunciphisa ubunzima ngokweklinikhi yayibetha:

• ≥5% ukulahleka kwesisindo: 27% kunye ne-placebo vs. 92-100% kumaqela asebenzayo

• ≥10%: 9% kunye ne-placebo vs. 73-93% kumaqela asebenzayo

• ≥15%: I-2% ene-placebo vs. 55-83% kumaqela asebenzayo

Kwiqela le-12 mg, ukuya kuthi gaI-26% yabathathi-nxaxheba balahlekelwe ≥30% yobunzima babo besiseko, ubungakanani bokuncipha kobunzima obuthelekiswa notyando lwe-bariatric.

Ukhuseleko
Ezona ziganeko zibi zixhaphake kakhulu ibisisisulelo (isicaphucaphu, ukugabha, urhudo), ngokuqhelekileyo luphakathi ukuya phakathi kwaye lunxulumene nedosi. Amanani okuqala asezantsi (2 mg titration) anciphisa ezi ziganeko. Ukunyuka okuhambelana ne-dose kwizinga lentliziyo kwabonwa, ukunyuka kwiveki ye-24, emva koko kwehla. Amazinga okuphelisa asusela kwi-6-16% kumaqela asebenzayo, angaphezulu kancinci kune-placebo.

Izigqibo
Kubantu abadala abatyebe kakhulu ngaphandle kweswekile, i-retatrutide ye-subcutaneous yeveki ngeeveki ze-48 ziveliswakakhulu, ukunciphisa okuxhomekeke kwithamo kubunzima bomzimba(ukuya kuthi ga kwi- ~ 24% ithetha ilahleko kwidosi ephezulu), kunye nokuphuculwa kweempawu ze-cardiometabolic. Iziganeko ezimbi zesisu zesisu zazihlala rhoqo kodwa zilawuleka nge-titration. Ezi ziphumo zesigaba se-2 zibonisa ukuba i-retatrutide inokumela i-benchmark entsha yonyango yokukhuluphala, ilindele ukuqinisekiswa kwizilingo ezinkulu, zexesha elide le-3.